A Stability Indicating RP‐HPLC Method for Determination of Foslevodopa and Foscarbidopa in Bulk and Formulation DOI

Ravisankar Panchumarthy,

Srilakshmi Bathula,

Bhagavan Rajesh Babu Koppisetty

и другие.

Separation Science Plus, Год журнала: 2025, Номер 8(5)

Опубликована: Май 1, 2025

ABSTRACT The recently approved combination of foslevodopa and foscarbidopa by the United States Food Drug Administration provides a major advancement in treatment Parkinson's disease. This therapy helps to maintain consistent plasma levels levodopa, thereby minimizing overall symptom patients. A robust validated RP‐HPLC method has been developed due novelty drug its recent approval regulatory agencies. optimized chromatographic conditions included use C18 column (250 × 4.6 mm, 5 µm), an isocratic mobile phase acetonitrile: 0.1% formic acid (30:70), flow rate 1.0 mL/min, injection volume 10 µL, detection at 272 nm, ambient temperature 25°C, with total runtime 6 min. Under these conditions, eluted 2.087 min 4.166 System suitability parameters, including plate count, tailing factor, %RSD, were within acceptable limits. exhibited high precision, %RSD values below 2%, excellent linearity over concentration range 30–180 µg/mL for 1.5–9 foscarbidopa. Sensitivity analysis determined LOD LOQ 0.480 1.700 0.024 0.084 foscarbidopa, respectively. Degradation studies confirmed stability indicating capability under various stress oxidative causing highest degradation. was applied assay pharmaceutical formulation confirming compliance label claims.

Язык: Английский

Levodopa Pharmacokinetics in Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient with Parkinson's Disease: a case report DOI Creative Commons

Tomonori Nukariya,

Toshiki Tezuka, Shohei Okusa

и другие.

Journal of Movement Disorders, Год журнала: 2025, Номер unknown

Опубликована: Янв. 6, 2025

Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms including bradykinesia, rigidity, tremor, and postural instability [1].In advanced stages, PD patients often suffer from fluctuations due to narrowed therapeutic window, some of whom will be suitable candidates for device-aided therapies

Язык: Английский

Процитировано

1
Managing cognitive impairment in Parkinson’s disease: an update of the literature DOI
Jennifer G. Goldman, Priya Jagota, Elie Matar

и другие.

Expert Review of Neurotherapeutics, Год журнала: 2025, Номер unknown, С. 1 - 21

Опубликована: Янв. 7, 2025

Introduction Cognitive impairment in Parkinson's disease (PD) substantially affects patient outcomes, function, and quality of life. PD-related cognitive dysfunction is often heterogeneous clinical presentation rates progression. As changes occur many people with PD, it essential to evaluate cognition, provide education, implement management strategies for symptoms.

Язык: Английский

Процитировано

1
The interplay of iron, oxidative stress, and α-synuclein in Parkinson’s disease progression DOI Creative Commons
Yan Chen,

Xixi Luo,

Yonggao Yin

и другие.

Molecular Medicine, Год журнала: 2025, Номер 31(1)

Опубликована: Апрель 26, 2025

Abstract The irreversible degeneration of dopamine neurons induced by α-synuclein (α-syn) aggregation in the substantia nigra is central pathological feature Parkinson's disease (PD). Neuroimaging and autopsy studies consistently confirm significant iron accumulation brain PD patients, suggesting a critical role for progression. Current research has established that overload induces ferroptosis dopaminergic neurons, evidence indicates impact on pathology extends beyond ferroptosis. Iron also plays regulatory modulating α-syn, affecting its aggregation, spatial conformation, post-translational modifications, mRNA stability. Iron-induced α-syn can contribute to neurodegeneration through additional mechanisms, potentially creating feedback loop which further enhances accumulation, thus perpetuating vicious cycle neurotoxicity. Given α-syn’s intrinsically disordered structure, targeting metabolism presents promising therapeutic strategy PD. Therefore, development chelators, alone or combination with other drugs, may offer beneficial approach alleviating symptoms slowing

Язык: Английский

Процитировано

1
Device-assisted therapies for Parkinson disease. DOI
Nadia Mouchaileh, Jillian M. Cameron

PubMed, Год журнала: 2025, Номер 48(1), С. 10 - 17

Опубликована: Фев. 1, 2025

Device-assisted therapies for Parkinson disease include apomorphine continuous subcutaneous infusion, levodopa intestinal gel infusion and deep brain stimulation. These have a role in managing motor fluctuations dyskinesias people with advanced when symptoms are inadequately controlled oral transdermal treatments. Subcutaneous of or the least invasive device-assisted therapies. Levodopa is delivered via surgically placed tube. Deep stimulation involves implanting electrodes into specific target regions basal ganglia to modulate activity. Selecting an appropriate therapy depends on individual factors such as age, comorbidities, symptom severity patient preferences. Initiation management require neurologist multidisciplinary involvement, typically specialist movement disorder centre. Primary care clinicians play crucial ongoing support using these therapies, including monitoring adverse effects communicating services.

Язык: Английский

Процитировано

0
Advanced Parkinson’s disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study DOI
Mohamed Daghi, Zineb Serhier, Abdelhakim Lakhdar

и другие.

Neurodegenerative Disease Management, Год журнала: 2025, Номер unknown, С. 1 - 12

Опубликована: Март 24, 2025

Aim This study investigates the prevalence and clinical features of advanced Parkinson's disease (APD) in Moroccan patients evaluates their eligibility for Device-Aided Therapies (DATs), including Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa-Carbidopa Intestinal Gel infusion (LCIG).

Язык: Английский

Процитировано

0
Managing impulse control and related behavioral disorders in Parkinson’s disease: where we are in 2025? DOI
Leonardo Rigon,

Carmelo Fogliano,

К. Ray Chaudhuri

и другие.

Expert Review of Neurotherapeutics, Год журнала: 2025, Номер unknown

Опубликована: Март 28, 2025

Introduction Impulse control and related behavioral disorders (ICBDs) commonly complicate Parkinson's disease (PD) course. The ICBDs spectrum encompasses two groups of conditions, with distinct pathophysiology: proper 'impulse (ICDs)' (e.g. gambling) the 'ICDs (ICDs-RD)' punding). Behavioral disturbances are associated dopamine replacement therapies. significantly affect quality life patients caregivers, making their management essential for reducing overall burden PD.

Язык: Английский

Процитировано

0
Device-aided therapies (DATs) in Parkinson’s disease (PD). The DATs-PD GETM Spanish Registry Protocol Study DOI Creative Commons
Diego Santos‐García, Guillermo González‐Ortega, Pilar Sánchez Alonso

и другие.

PLoS ONE, Год журнала: 2025, Номер 20(3), С. e0316052 - e0316052

Опубликована: Март 31, 2025

Background and objective Device-aided therapies (DATs) are treatments indicated for people with Parkinson´s disease (PwP) experiencing clinical fluctuations that remain suboptimal despite conventional medication. New DATs have recently emerged such as levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) subcutaneous of foslevodopa/foscarbidopa (fLD/fCD). Understanding the differences between various is essential. Patients Methods We present here protocol study DATs-PD GETM Spanish Registry. This a descriptive, observational, prospective, multicenter, open proposed registry progressive inclusion PwP treated DAT in daily practice conditions more 40 centers from Spain 10 years. The principal aim to know type our country (Spain) receive. Specific objectives compare characteristics patients, effectiveness, safety tolerability, identify predictors good response analyze by groups (gender, duration, phenotype, etc.). There baseline visit (V1; indication therapy), start (V2; initiation therapy) follow-up visits at 6 months ± 3 (V3_6M) after this annually years (V3_12M, V3_24M, Results on going. first patient was included April 10, 2024. Patient recruitment will be conducted until 31/DEC/2033. It estimated include minimum 3,000 patients. Conclusion help improve care PD patients DAT.

Язык: Английский

Процитировано

0
Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson’s Disease DOI

Hannah A. Blair

CNS Drugs, Год журнала: 2025, Номер unknown

Опубликована: Апрель 8, 2025

Язык: Английский

Процитировано

0
A Stability Indicating RP‐HPLC Method for Determination of Foslevodopa and Foscarbidopa in Bulk and Formulation DOI

Ravisankar Panchumarthy,

Srilakshmi Bathula,

Bhagavan Rajesh Babu Koppisetty

и другие.

Separation Science Plus, Год журнала: 2025, Номер 8(5)

Опубликована: Май 1, 2025

ABSTRACT The recently approved combination of foslevodopa and foscarbidopa by the United States Food Drug Administration provides a major advancement in treatment Parkinson's disease. This therapy helps to maintain consistent plasma levels levodopa, thereby minimizing overall symptom patients. A robust validated RP‐HPLC method has been developed due novelty drug its recent approval regulatory agencies. optimized chromatographic conditions included use C18 column (250 × 4.6 mm, 5 µm), an isocratic mobile phase acetonitrile: 0.1% formic acid (30:70), flow rate 1.0 mL/min, injection volume 10 µL, detection at 272 nm, ambient temperature 25°C, with total runtime 6 min. Under these conditions, eluted 2.087 min 4.166 System suitability parameters, including plate count, tailing factor, %RSD, were within acceptable limits. exhibited high precision, %RSD values below 2%, excellent linearity over concentration range 30–180 µg/mL for 1.5–9 foscarbidopa. Sensitivity analysis determined LOD LOQ 0.480 1.700 0.024 0.084 foscarbidopa, respectively. Degradation studies confirmed stability indicating capability under various stress oxidative causing highest degradation. was applied assay pharmaceutical formulation confirming compliance label claims.

Язык: Английский

Процитировано

0